Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 4/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | ACACB | O00763 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969486 | 0.90 | ESR1 (0.53) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968748 | 0.90 | ACACA (0.46) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968050 | 0.88 | MAPT (0.50) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968358 | 0.87 | ACACB (0.46) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968690 | 0.86 | ACACA (0.43) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968555 | 0.86 | ACACA (0.46) | ACACAACACBMAPT | |
| SCHEMBL15968697 | 0.86 | ACACA (0.46) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968486 | 0.86 | ACACA (0.43) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL14908412 | 0.86 | ACACA (0.45) | ACACAMTNR1AMTNR1BACACBMAPT | |
| SCHEMBL15968313 | 0.86 | ACACA (0.43) | ACACAMTNR1AMTNR1BACACBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ACACA 670/4885MTNR1A 3038/4885MTNR1B 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.